Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

08/12/20	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/02/20	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	153K 137K 126K 115K 214K 14.57M 218K 1.51M 605K 7.66M 576K 563K 24.16M	P/E 2014	-0.87x	P/E 2015	-1.04x
Enterprise Value	20.01M 17.92M 16.48M 14.94M 27.92M 1.9B 28.44M 197M 78.92M 999M 75.1M 73.5M 3.15B	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

08/12/20	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
06/02/20	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
21/12/18	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
11/01/18	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
27/09/16	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
30/08/16	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
11/08/16	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
09/07/16	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
08/06/16	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
30/03/16	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
23/03/16	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
22/03/16	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
19/11/15	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ROCK CREEK PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	17.04K
ELI LILLY AND COMPANY	+3.19%	+11.31%	+67.86%	+150.58%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.51%	+85.81%	658B
ABBVIE INC.	+1.41%	+3.24%	+29.22%	+107.83%	521B
ROCHE HOLDING AG	+0.42%	+3.20%	+54.15%	+67.18%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.30%	+45.62%	369B
NOVARTIS AG	+1.12%	+4.52%	+35.30%	+58.08%	307B
ASTRAZENECA PLC	+6.96%	+8.86%	+11.27%	+36.62%	290B
AMGEN INC.	+1.15%	+6.09%	+59.59%	+77.06%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+44.11%	+119.47%	212B
Average	+1.56%	+5.31%	+46.59%	+83.14%	426.19B
Weighted average by Cap.	+1.19%	+6.60%	+50.88%	+98.31%

Rock Creek Pharmaceuticals, Inc. Stock

Stocks

RCPIQ

US7720812046

Pharmaceuticals

Valuation: Rock Creek Pharmaceuticals, Inc.

Latest news: Rock Creek Pharmaceuticals, Inc.

Analysts' recommendations: Rock Creek Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

	2014	2015
Net sales	-	-
Net income	-38.52M -34.5M -31.73M -28.75M -53.74M -3.66B -54.75M -378M -152M -1.92B -145M -141M -6.07B	-6.84M -6.13M -5.64M -5.11M -9.55M -650M -9.73M -67.25M -26.99M -342M -25.69M -25.14M -1.08B
Net Debt	-45K -40.3K -37.07K -33.59K -62.79K -4.27M -63.96K -442K -177K -2.25M -169K -165K -7.09M	19.86M 17.78M 16.36M 14.82M 27.71M 1.89B 28.22M 195M 78.31M 992M 74.52M 72.94M 3.13B